Abstract
Background
Radical lymph node (LN) dissection along the recurrent laryngeal nerve (RLN) area carries a substantial morbidity rate, and its usefulness in neoadjuvant chemoradiotherapy (nCRT)-treated esophageal cancer patients remains unclear.
Methods
This study was conducted in two Asian thoracic surgery centers. Patients with esophageal squamous cell carcinoma (ESCC) who were judged to be ycN-RLN(−) after nCRT and received bilateral RLN LN dissection were eligible. The incidence of unsuspected RLN LN involvement was analyzed, and we used least absolute shrinkage and selection operator (LASSO) regression to identify its predictors.
Results
A total of 56 patients (53 males and 3 females; mean age: 55 years) were included. The upper mediastinum—including the bilateral RLN area—was covered by the radiation field in 48 (85.3%) patients. Although all of them were judged as ycN-RLN(−), unsuspected RLN LN involvement was identified on pathological examination in 11 (19.6%) subjects, being the only positive nodal station in seven. LASSO regression identified the pre-nCRT RLN LN(cN-RLN) status as the only independent predictor of ypN-RLN positivity; in contrast, neither the tumor location nor the radiation dose to the upper mediastinum were independently associated with ypN-RLN(+). RLN nodal dissection resulted in positive LN discovery rates of 30.8 and 10% in ycN-RLN(−) patients who had positive and negative cN-RLNs before nCRT, respectively. Consequently, 23.1 and 6.7% of patients in each subgroup would have been understaged in the absence of RLN nodal dissection.
Conclusion
Nearly one-fifth of ESCC patients who were judged to be ycN-RLN(−) unexpectedly had positive ypN-RLN. The pre-nCRT cN-RLN status plays a key role in the selection of patients that should undergo RLN LN dissection after nCRT.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Li B, Chen H, Xiang J et al (2012) Pattern of lymphatic spread in thoracic esophageal squamous cell carcinoma: a single-institution experience. J Thorac Cardiovasc Surg 144:778–786
Udagawa H, Ueno M, Shinohara H et al (2012) The importance of grouping of lymph node stations and rationale of three-field lymphoadenectomy for thoracic esophageal cancer. J Surg Oncol 106:742–747
Tachimori Y, Ozawa S, Numasaki H et al (2016) Efficacy of lymph node dissection for each station based on esophageal tumor location. Esophagus 13:138–145
Tan Z, Ma G, Zhao J et al (2014) Impact of thoracic recurrent laryngeal node dissection: 508 patients with tri-incisional esophagectomy. J Gastrointest Surg 18:187–193
Sato Y, Kosugi S-I, Aizawa N et al (2016) Risk factors and clinical outcomes of recurrent laryngeal nerve paralysis after esophagectomy for thoracic esophageal carcinoma. World J Surg 40:129–136. https://doi.org/10.1007/s00268-015-3261-8
Fujita H, Sueyoshi S, Tanaka T et al (2003) Optimal lymphadenectomy for squamous cell carcinoma in the thoracic esophagus: comparing the short-and long-term outcome among the four types of lymphadenectomy. World J Surg 27:571–579. https://doi.org/10.1007/s00268-003-6913-z
Pertl L, Zacherl J, Mancusi G et al (2011) High risk of unilateral recurrent laryngeal nerve paralysis after esophagectomy using cervical anastomosis. Eur Arch Otorhinolaryngol 268:1605–1610
Sjoquist KM, Burmeister BH, Smithers BM et al (2011) Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol 12:681–692
Shapiro J, van Lanschot JJB, Hulshof MC et al (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16:1090–1098
van Hagen P, Hulshof M, Van Lanschot J et al (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 366:2074–2084
Talsma AK, Shapiro J, Looman CW et al (2014) Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg 260:786–793
Shridhar R, Hoffe SE, Almhanna K et al (2013) Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol 20:3038–3043
Rice TW, Ishwaran H, Ferguson MK et al (2017) Cancer of the esophagus and esophagogastric junction: an eighth edition staging primer. J Thorac Oncology 12:36–42
Wong B (1994) More or less surgery for esophageal cancer: extent of lymphadenectomy in esophagectomy for squamous cell esophageal carcinoma How much is necessary. Dis Esoph 7:151–155
Low DE, Alderson D, Cecconello I et al (2015) International consensus on standardization of data collection for complications associated with esophagectomy: esophagectomy complications consensus group (ECCG). Ann Surg 262:286–294
Van Der Sluis PC, Verhage RJ, Van Der Horst S et al (2014) A new clinical scoring system to define pneumonia following esophagectomy for cancer. Digestive surgery 31:108–116
Hsu H-Y, Chao Y-K, Hsieh C-H et al (2016) Postoperative adjuvant therapy improves survival in pathologic nonresponders after neoadjuvant chemoradiation for esophageal squamous cell carcinoma: a propensity-matched analysis. Ann Thorac Surg 102:1687–1693
Fyles AW, Milosevic M, Wong R et al (1998) Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother Oncol 48:149–156
Funding
This study was supported by grant (CMRPG3G0291) from the Chang Gung Memorial Hospital, Taiwan.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Rights and permissions
About this article
Cite this article
Li, ZG., Zhang, XB., Wen, YW. et al. Incidence and Predictors of Unsuspected Recurrent Laryngeal Nerve Lymph Node Metastases After Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma. World J Surg 42, 2485–2492 (2018). https://doi.org/10.1007/s00268-018-4516-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00268-018-4516-y